Cyclin-Dependent Kinase 6 Inhibits Proliferation of Human Mammary Epithelial Cells

Molecular Cancer Research

Volumn 2, Issue 2, 2004, Pages 105-114

  Lucas, Joseph J ^a   Domenico, Joanne ^a   Gelfand, Erwin W ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; PROTEIN P130; TRANSCRIPTION FACTOR E2F4;

ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA TRANSFECTION; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR GROWTH;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASES; DNA-BINDING PROTEINS; E2F4 TRANSCRIPTION FACTOR; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, HUMAN; PROTEINS; RETINOBLASTOMA-LIKE PROTEIN P130; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 1342322841     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Sherr CJ. Cancer cell cycles revisited. Cancer Res, 2000;60:3689-95.
2. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell, 2002;2:103-12.
3. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell, 1995;81:323-30.
4. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet, 2001;10:699-703.
5. Stevaux S, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol, 2002;14:684-91.
6. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol, 2002;3:11-20.
7. Lees JA, Buchkovich KJ, Marshak DR, Anderson CW, Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J, 1991;10:4279-90.
8. DeCaprio JA, Furukawa T, Ajchenbaum F, Griffin JD, Livingston DM. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA, 1992;89:1795-8.
9. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci USA, 1997;94:10699-704.
10. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol, 2001;21:4773-84.
11. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol, 1998;18:753-61.
12. 1 block. EMBO J, 2001;20:422-32.
13. Morgan DO. Principles of CDK regulation. Nature, 1995;374:131-4.
14. 1-phase progression. Genes Dev, 1999;13:1501-12.
15. Buckley MF, Sweeney KJE, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 1993;8:2127-33.
16. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res, 1994;54:1812-7.
17. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA, 1993;90:1112-6.
18. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci USA, 1995;92:5386-90.
19. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med, 2002;347:1566-75.
20. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet, 1995;11:210-2.
21. Brenner AJ, Paladugu A, Wang H, Olopade OI, Dreyling MH, Aldaz CM. Preferential loss of expression of p16(Ink4a) rather than p19(ARF) in breast cancer. Clin Cancer Res, 1996;2:1993-8.
22. Kip1 protein: prognostic implications in primary breast cancer. Nat Med, 1997;3:227-30.
23. Tan P, Cady B, Warmer M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res, 1997;57:1259-63.
24. 1 arrest. Nat Med, 2002;8:1153-60.
25. Shin I, Yakes FM, Rojo F, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med, 2002;8:1145-52.
26. Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med, 2002;8:1136-44.
27. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev, 2000;14:2393-409.
28. Chan HM, Krstic-Demonacos M, Smith L, Demonacas C, La Thangue NB. Acetylation control of the retinoblastoma tumor-suppressor protein. Nat Cell Biol, 2001;3:667-74.
29. Classon M, Dyson N. P107 and p130: versatile proteins with interesting pockets. Exp Cell Res, 2001;264:135-47.
30. 1-S cyclin-dependent kinases. J Biol Chem, 1997;272:12738-46.
31. Farkas T, Hansen K, Holm K, Lukas J, Bartek J. Distinct phosphorylation events regulate p130- and p107-mediated repression of E2F4. J Biol Chem, 2002;277:26741-52.
32. Ewen ME. Where the cell cycle and histones meet. Genes Dev, 2000;14:2265-70.
33. Ho A, Dowdy SF. Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev, 2002;12:47-52.
34. Sherr CJ. Cancer cell cycles. Science, 1996;274:1672-7.
35. Meyerson M, Enders GH, Wu CL, et al. A family of human cdc2-related protein kinases. EMBO J, 1992;11:2909-17.
36. 1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol, 1994;14:2077-86.
37. Lucas JJ, Szepesi A, Modiano JF, Domenico J, Gelfand EW. Regulation of synthesis and activity of the PLSTIRE protein (cyclin-dependent kinase 6 (cdk6)), a major cyclin D-associated cdk4 homologue in normal human T lymphocytes. J Immunol, 1995;154:6275-84.
38. 1 progression. Oncogene, 1994;9:2663-74.
39. Modiano JF, Domenico J, Szepesi A, Terada N, Lucas JJ, Gelfand EW. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells. J Biol Chem, 1994;269:32972-8.
40. Lucas JJ, Szepesi A, Domenico J, et al. Differential regulation of the synthesis and activity of the major cyclin-dependent kinases, p34cdc2, p33cdk2, and p34cdk4, during cell cycle entry and progression in normal human T lymphocytes. J Cell Physiol, 1995;165:406-16.
41. Nagasawa M, Melamed I, Kupfer A, Gelfand EW, Lucas JJ. Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation. J Immunol, 1997;158:5146-54.
42. Nagasawa M, Gelfand EW, Lucas JJ. Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6). Oncogene, 2001;20:2889-99.
43. Matushansky I, Radparvar F, Skoultchi AI. Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors. Blood, 2000;96:2755-64.
44. Ericson KK, Krull D, Slomiany P, Grossel MJ. Expression of cyclin-dependent kinase 6, but not cyclin-dependent kinase 4, alters morphology of cultured mouse astrocytes. Mol Cancer Res, 2003;1:654-64.
45. Rayman J, Takahashi B, Indjeian Y, et al. E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDACI/mSin3B corepressor complex. Genes Dev, 2002;16:933-47.
46. Stampfer MR, Bartley JC. Human mammary epithelial cells in culture: differentiation and transformation. Cancer Treat Res, 1988;40:1-24.
47. Barranco SC, Perry RR, Durm ME, et al. Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy. Cancer Res, 1994;54:5351-6.
48. Symmans WF, Liu J, Knowles DM, Inghirami G. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol, 1995;26:210-6.
49. Thornborrow EC, Manfredi JJ. The tumor suppressor protein p53 requires a cofactor to activate transcriptionally the human BAX promoter. J Biol Chem, 1999;274:33747-56.
50. 1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res, 1996;56:2973-8.
51. Taylor-Papadimitriou J, Stampfer M, Bartek J, et al. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J Cell Sci, 1989;94:403-13.
52. Grossel MJ, Baker GL, Hinds PW. Cdk6 can shorten G(1) phase dependent upon the N-terminal INK4 interaction domain. J Biol Chem, 1999;333:29960-7.
53. Ojala PM, Tiainen M, Salven P, et al. Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res, 1999;59:4984-9.
54. Ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA, 1995;92:6289-93.
55. 1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem, 1998;273:3838-47.
56. Rahman KMW, Aranha O, Glazyrin A, Chinni S, Sarkar FH. Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (13C) treated breast cancer cells. Oncogene, 2000;19:5764-71.
57. 1-phase traverse in 1, 25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res, 1997;57:2851-5.
58. Kip1. Endocrinology, 2000;141:3931-9.
59. Zhang F, Taipale M, Heiskanen A, Laiho M. Ectopic expression of Cdk6 circumvents transforming growth factor-β mediated growth inhibition. Oncogene, 2001;20:5888-96.
60. Timmermann S, Hinds PW, Mungenn K. Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines. Cell Growth & Differ, 1997;8:361-70.
61. Costello JF, Plass C, Arap W, et al. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res, 1997;57:1250-4.
62. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res, 1998;58:2170-5.
63. Kannan K, Sharpless NE, Xu J, O'Hagan RC, Bosenberg M, Chin L. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA, 2003;100:1221-5.
64. Chilosi M, Doglioni C, Yan Z, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol, 1998;152:209-17.
65. Sauter ER, Yeo U-C, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res, 2002;62:3200-6.
66. Van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science, 1993;262:2050-4.
67. Garriga J, Limon A, Mayol X, et al. Differential regulation of the retinoblastoma family of proteins during cell proliferation and diffenentiation. Biochem J, 1998;333:645-54.
68. Smith EJ, Leone G, Nevins JR. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth & Differ, 1998;9:297-303.
69. 1 cyclin/CDK coordinated phosphorylation of endogenous pocket proteins differentially regulates their interactions with E2F4 and E2F1 and gene expression. J Biol Chem, 2002;277:50263-74.
70. 1 phase of the cell cycle. Cell, 1991;65:701-13.
71. Won K, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA, 1992;89:9910-4.
72. Lindeman G, Gaubatz J, Livingston DM, Ginsberg D. The subcellular localization of E2F-4 is cell-cycle dependent. Proc Natl Acad Sci USA, 1997;94:5095-100.
73. Verona R, Moberg K, Estes S, Starz M, Vernon JP, Lees JA. E2F activity is regulated by cell cycle-dependent changes in subcellular localization. Mol Cell Biol, 1997;17:7268-82.
74. 1-S transition and DNA replication. Cancer Cell, 2003;3:311-6.
75. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRb, p107 and p130 in the negative control of cell growth. Oncogene, 1998;17:3365-83.
76. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem, 2000;275:38221-9.
77. Said TK, Moraes RCB, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res, 2001;3:122-33.
78. Miranda LR, Schaefer BC, Kupfer A, Hu Z, Frazusoff A. Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. Proc Natl Acad Sci USA, 2002;99:8031-6.